{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T11:52:29Z","timestamp":1790509949275,"version":"4.1.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"National Nature Science Foundation","award":["81771436"],"award-info":[{"award-number":["81771436"]}]},{"name":"National Nature Science Foundation","award":["U1502228"],"award-info":[{"award-number":["U1502228"]}]},{"DOI":"10.13039\/501100014175","name":"Shanghai Municipal Health and Family Planning Commission","doi-asserted-by":"crossref","award":["2014ZYJB0002"],"award-info":[{"award-number":["2014ZYJB0002"]}],"id":[{"id":"10.13039\/501100014175","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Shanghai Key Laboratory of Psychotic Disorders","award":["13DZ2260500"],"award-info":[{"award-number":["13DZ2260500"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","jocn-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Neuroscience"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.jocn.2017.08.042","type":"journal-article","created":{"date-parts":[[2017,9,12]],"date-time":"2017-09-12T07:31:37Z","timestamp":1505201497000},"page":"9-12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Endocannabinoid mechanism in amphetamine-type stimulant use disorders: A short review"],"prefix":"10.1016","volume":"46","author":[{"given":"Hang","family":"Su","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jocn.2017.08.042_b0005","series-title":"World Drug Report 2015","author":"Crime UNOoDa","year":"2015"},{"key":"10.1016\/j.jocn.2017.08.042_b0010","unstructured":"Committee CNNC. Annual National Narcotic Control Report 2015. Beijing, China, 2015."},{"key":"10.1016\/j.jocn.2017.08.042_b0015","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.pnpbp.2016.04.005","article-title":"The cognitive impairments and psychological wellbeing of methamphetamine dependent patients compared with health controls","volume":"69","author":"Zhong","year":"2016","journal-title":"Prog Neuro-psychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.jocn.2017.08.042_b0020","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2741\/S371","article-title":"Presynaptic dopamine modulation by stimulant self-administration","volume":"5","author":"Espana","year":"2013","journal-title":"Front Biosci (Schol Ed)"},{"key":"10.1016\/j.jocn.2017.08.042_b0025","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/bs.irn.2015.10.004","article-title":"Endocannabinoid signaling in motivation, reward, and addiction: influences on mesocorticolimbic dopamine function","volume":"125","author":"Sagheddu","year":"2015","journal-title":"Int Rev Neurobiol"},{"key":"10.1016\/j.jocn.2017.08.042_b0030","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0006-8993(97)01281-X","article-title":"Methamphetamine-induced alterations in dopamine transporter function","volume":"782","author":"Bennett","year":"1998","journal-title":"Brain Res"},{"key":"10.1016\/j.jocn.2017.08.042_b0035","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1046\/j.1471-4159.2000.0742221.x","article-title":"Methamphetamine rapidly decreases vesicular dopamine uptake","volume":"74","author":"Brown","year":"2000","journal-title":"J Neurochem"},{"key":"10.1016\/j.jocn.2017.08.042_b0040","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.1523\/JNEUROSCI.0387-04.2004","article-title":"Methamphetamine increases dopamine transporter higher molecular weight complex formation via a dopamine- and hyperthermia-associated mechanism","volume":"24","author":"Baucum","year":"2004","journal-title":"J Neurosci"},{"key":"10.1016\/j.jocn.2017.08.042_b0045","doi-asserted-by":"crossref","first-page":"162","DOI":"10.3389\/fncel.2015.00162","article-title":"The role of the GABA system in amphetamine-type stimulant use disorders","volume":"9","author":"Jiao","year":"2015","journal-title":"Front Cell Neurosci"},{"key":"10.1016\/j.jocn.2017.08.042_b0050","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/npp.2012.169","article-title":"Epigenetics of methamphetamine-induced changes in glutamate function","volume":"38","author":"Cadet","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jocn.2017.08.042_b0055","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1038\/npp.2015.351","article-title":"Differential control of cocaine self-administration by GABAergic and Glutamatergic CB1 cannabinoid receptors","volume":"41","author":"Martin-Garcia","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jocn.2017.08.042_b0060","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.neuro.2011.10.001","article-title":"Amphetamine differentially modifies the expression of monoaminergic and GABAergic synaptic boutons and processes in lateral habenula, dorsal and ventral hippocampal formation","volume":"33","author":"Yin","year":"2012","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.jocn.2017.08.042_b0065","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.nbd.2013.11.001","article-title":"The role of cannabinoid 1 receptor expressing interneurons in behavior","volume":"63","author":"Brown","year":"2014","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.jocn.2017.08.042_b0070","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/nm1349","article-title":"Disruption of PTEN coupling with 5-HT2C receptors suppresses behavioral responses induced by drugs of abuse","volume":"12","author":"Ji","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.jocn.2017.08.042_b0075","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/nrn4004","article-title":"Endocannabinoid signalling in reward and addiction","volume":"16","author":"Parsons","year":"2015","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.jocn.2017.08.042_b0080","doi-asserted-by":"crossref","DOI":"10.1007\/3-540-26573-2_10","article-title":"Distribution of cannabinoid receptors in the central and peripheral nervous system","volume":"299\u2013325","author":"Mackie","year":"2005","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.jocn.2017.08.042_b0085","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/sj.bjp.0707442","article-title":"The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin","volume":"153","author":"Pertwee","year":"2008","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jocn.2017.08.042_b0090","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1159\/000100778","article-title":"Neuropsychobiological evidence for the functional presence and expression of cannabinoid CB2 receptors in the brain","volume":"54","author":"Onaivi","year":"2006","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.jocn.2017.08.042_b0095","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/j.bcp.2003.12.003","article-title":"Monoglyceride lipase-like enzymatic activity is responsible for hydrolysis of 2-arachidonoylglycerol in rat cerebellar membranes","volume":"67","author":"Saario","year":"2004","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.jocn.2017.08.042_b0100","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1006\/bbrc.1997.7180","article-title":"Reversible hydrolysis and synthesis of anandamide demonstrated by recombinant rat fatty-acid amide hydrolase","volume":"237","author":"Kurahashi","year":"1997","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jocn.2017.08.042_b0105","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.neuint.2012.03.002","article-title":"Effects of amphetamine on dopamine release in the rat nucleus accumbens shell region depend on cannabinoid CB1 receptor activation","volume":"60","author":"Kleijn","year":"2012","journal-title":"Neurochem Int"},{"key":"10.1016\/j.jocn.2017.08.042_b0110","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.neulet.2010.12.013","article-title":"Local pretreatment with the cannabinoid CB1 receptor antagonist AM251 attenuates methamphetamine intra-accumbens self-administration","volume":"489","author":"Rodriguez","year":"2011","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.jocn.2017.08.042_b0115","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0166-4328(00)00311-9","article-title":"Cannabinoid CB1 receptor knockout mice fail to self-administer morphine but not other drugs of abuse","volume":"118","author":"Cossu","year":"2001","journal-title":"Behaviour Brain Res"},{"key":"10.1016\/j.jocn.2017.08.042_b0120","doi-asserted-by":"crossref","first-page":"e25856","DOI":"10.1371\/journal.pone.0025856","article-title":"Cannabinoid CB1 receptor activation mediates the opposing effects of amphetamine on impulsive action and impulsive choice","volume":"6","author":"Wiskerke","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.jocn.2017.08.042_b0125","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.biopsych.2009.09.024","article-title":"Brain cannabinoid CB2 receptor in schizophrenia","volume":"67","author":"Ishiguro","year":"2010","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.jocn.2017.08.042_b0130","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1097\/00001756-199701200-00023","article-title":"Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat","volume":"8","author":"Navarro","year":"1997","journal-title":"Neuroreport"},{"key":"10.1016\/j.jocn.2017.08.042_b0135","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s00213-001-0946-5","article-title":"Involvement of CB1 cannabinoid receptors in emotional behaviour","volume":"159","author":"Martin","year":"2002","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.jocn.2017.08.042_b0140","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.pbb.2011.07.011","article-title":"Acute blockade of CB1 receptor leads to reinstatement of MDMA-induced conditioned place preference","volume":"100","author":"Daza-Losada","year":"2011","journal-title":"Pharmacol Biochem Behavior"},{"key":"10.1016\/j.jocn.2017.08.042_b0145","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.bbr.2010.10.008","article-title":"Effects of cannabinoid CB(1) receptor antagonist rimonabant on acquisition and reinstatement of psychostimulant reward memory in mice","volume":"217","author":"Yu","year":"2011","journal-title":"Behaviour Brain Res"},{"key":"10.1016\/j.jocn.2017.08.042_b0150","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.neuropharm.2012.04.036","article-title":"Cannabinoid receptors mediate methamphetamine induction of high frequency gamma oscillations in the nucleus accumbens","volume":"63","author":"Morra","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jocn.2017.08.042_b0155","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1038\/sj.npp.1300454","article-title":"Endocannabinoid system modulates relapse to methamphetamine seeking: possible mediation by the arachidonic acid cascade","volume":"29","author":"Anggadiredja","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jocn.2017.08.042_b0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brainresrev.2006.05.003","article-title":"An endocannabinoid mechanism in relapse to drug seeking: a review of animal studies and clinical perspectives","volume":"53","author":"Fattore","year":"2007","journal-title":"Brain Res Rev"},{"key":"10.1016\/j.jocn.2017.08.042_b0165","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.neuropharm.2008.08.012","article-title":"Methamphetamine-seeking behavior is due to inhibition of nicotinic cholinergic transmission by activation of cannabinoid CB1 receptors","volume":"55","author":"Hiranita","year":"2008","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jocn.2017.08.042_b0170","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s00213-003-1393-2","article-title":"Brain circuitry and the reinstatement of cocaine-seeking behavior","volume":"168","author":"Kalivas","year":"2003","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.jocn.2017.08.042_b0175","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00213-002-1224-x","article-title":"The reinstatement model of drug relapse: history, methodology and major findings","volume":"168","author":"Shaham","year":"2003","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.jocn.2017.08.042_b0180","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/npp.2013.231","article-title":"Dysregulation of dopamine and glutamate release in the prefrontal cortex and nucleus accumbens following methamphetamine self-administration and during reinstatement in rats","volume":"39","author":"Parsegian","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jocn.2017.08.042_b0185","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/jnc.12399","article-title":"Crosstalk between dopamine D(2) receptors and cannabinoid CB(1) receptors regulates CNR1 promoter activity via ERK1\/2 signaling","volume":"127","author":"Chiang","year":"2013","journal-title":"J Neurochem"},{"key":"10.1016\/j.jocn.2017.08.042_b0190","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/syn.21796","article-title":"Cannabinoid CB1 receptors activation and coactivation with D2 receptors modulate GABAergic neurotransmission in the globus pallidus and increase motor asymmetry","volume":"69","author":"Munoz-Arenas","year":"2015","journal-title":"Synapse"},{"key":"10.1016\/j.jocn.2017.08.042_b0195","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1111\/j.1460-9568.2010.07591.x","article-title":"Activation of D(2)-like receptors in rat ventral tegmental area inhibits cocaine-reinstated drug-seeking behavior","volume":"33","author":"Xue","year":"2011","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.jocn.2017.08.042_b0200","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1016\/j.neuropharm.2012.01.013","article-title":"Methamphetamine-induced dopamine terminal deficits in the nucleus accumbens are exacerbated by reward-associated cues and attenuated by CB1 receptor antagonism","volume":"62","author":"Loewinger","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jocn.2017.08.042_b0205","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1471-4159.2010.06578.x","article-title":"Evidence that MDMA ('ecstasy') increases cannabinoid CB2 receptor expression in microglial cells: role in the neuroinflammatory response in rat brain","volume":"113","author":"Torres","year":"2010","journal-title":"J Neurochem"},{"key":"10.1016\/j.jocn.2017.08.042_b0210","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/1742-2094-8-53","article-title":"Changes in interleukin-1 signal modulators induced by 3,4-methylenedioxymethamphetamine (MDMA): regulation by CB2 receptors and implications for neurotoxicity","volume":"8","author":"Torres","year":"2011","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.jocn.2017.08.042_b0215","doi-asserted-by":"crossref","first-page":"e9143","DOI":"10.1371\/journal.pone.0009143","article-title":"THC prevents MDMA neurotoxicity in mice","volume":"5","author":"Tourino","year":"2010","journal-title":"PloS one"},{"key":"10.1016\/j.jocn.2017.08.042_b0220","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.neuropharm.2014.03.014","article-title":"Prior stimulation of the endocannabinoid system prevents methamphetamine-induced dopaminergic neurotoxicity in the striatum through activation of CB2 receptors","volume":"87","author":"Nader","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jocn.2017.08.042_b0225","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/00008877-200509000-00012","article-title":"Persistent anxiogenic effects of a single or repeated doses of cocaine and methamphetamine: interactions with endogenous cannabinoid receptor ligands","volume":"16","author":"Hayase","year":"2005","journal-title":"Behaviour Pharmacol"},{"key":"10.1016\/j.jocn.2017.08.042_b0230","doi-asserted-by":"crossref","first-page":"6937","DOI":"10.1523\/JNEUROSCI.3936-06.2007","article-title":"Role of cannabinoid type 1 receptors in locomotor activity and striatal signaling in response to psychostimulants","volume":"27","author":"Corbille","year":"2007","journal-title":"J Neurosci"},{"key":"10.1016\/j.jocn.2017.08.042_b0235","first-page":"703","article-title":"Impact of cannabinoid receptor ligands on behavioural sensitization to antiaggressive methamphetamine effects in the model of mouse agonistic behaviour","volume":"27","author":"Landa","year":"2006","journal-title":"Neuro Endocrinol Lett"},{"key":"10.1016\/j.jocn.2017.08.042_b0240","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.pbb.2008.01.010","article-title":"The CB(1) cannabinoid receptor antagonist AM251 attenuates amphetamine-induced behavioural sensitization while causing monoamine changes in nucleus accumbens and hippocampus","volume":"89","author":"Thiemann","year":"2008","journal-title":"Pharmacol Biochem Behavior"},{"key":"10.1016\/j.jocn.2017.08.042_b0245","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.bbr.2007.09.022","article-title":"The role of the CB1 cannabinoid receptor and its endogenous ligands, anandamide and 2-arachidonoylglycerol, in amphetamine-induced behavioural sensitization","volume":"187","author":"Thiemann","year":"2008","journal-title":"Behaviour Brain Res"},{"key":"10.1016\/j.jocn.2017.08.042_b0250","first-page":"63","article-title":"Involvement of cannabinoid CB1 and CB2 receptor activity in the development of behavioural sensitization to methamphetamine effects in mice","volume":"27","author":"Landa","year":"2006","journal-title":"Neuro Endocrinol Lett"},{"key":"10.1016\/j.jocn.2017.08.042_b0255","first-page":"113","article-title":"Effects of the cannabinoid receptor ligands on anxiety-related effects of d-amphetamine and nicotine in the mouse elevated plus maze test","volume":"60","author":"Biala","year":"2009","journal-title":"J Physiol Pharmacol"},{"key":"10.1016\/j.jocn.2017.08.042_b0260","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.pbb.2005.01.029","article-title":"Endocannabinoid system and stress and anxiety responses","volume":"81","author":"Viveros","year":"2005","journal-title":"Pharmacol Biochem Behavior"},{"key":"10.1016\/j.jocn.2017.08.042_b0265","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.neubiorev.2006.08.002","article-title":"Nicotine and cannabinoids: parallels, contrasts and interactions","volume":"30","author":"Viveros","year":"2006","journal-title":"Neurosci Biobehavior Rev"},{"key":"10.1016\/j.jocn.2017.08.042_b0270","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/00008877-200402000-00003","article-title":"Involvement of 5-HT1A receptors in behavioural effects of the cannabinoid receptor agonist CP 55,940 in male rats","volume":"15","author":"Marco","year":"2004","journal-title":"Behaviour Pharmacol"}],"container-title":["Journal of Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096758681730989X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096758681730989X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,18]],"date-time":"2020-05-18T07:15:30Z","timestamp":1589786130000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S096758681730989X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":54,"alternative-id":["S096758681730989X"],"URL":"https:\/\/doi.org\/10.1016\/j.jocn.2017.08.042","relation":{},"ISSN":["0967-5868"],"issn-type":[{"value":"0967-5868","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Endocannabinoid mechanism in amphetamine-type stimulant use disorders: A short review","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocn.2017.08.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}